Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Objective: This study aimed to investigate the impact of vunakizumab on adverse events (AEs) in patients with moderate-to-severe plaque psoriasis. Methods: This exploratory post-hoc analysis used data from a phase III trial (NCT04839016). A total of 690 patients were included. The primary outcome was any AE occurrence during the 12-week induction treatment period. Results: The incidence of any AE during the induction period was 69.9%.
Methods This retrospective study included 189 breast cancer patients, who underwent NAC at the Second Hospital of Dalian Medical University between 2016 and 2022. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki was approved by the Medical Ethics Committee of Dalian Medical University Cancer Institute and Hospital.
A 69-year-old male Chinese farmer presented with bilateral facial lesions that had gradually worsened during the previous 20 years. He had a history of smoking (>10 cigarettes every day) for at least 30 years, but was otherwise healthy and denied any exposure to radiation, toxins, or chemicals. On physical examination, multiple solitary open black comedones were located bilaterally on the malar cheeks and temples.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
